NCT00796276 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | May 2004 | Phase 1 |
NCT00210717 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | February 2005 | Phase 3 |
NCT01258920 | Janssen Pharmaceutical K.K. | Schizophrenia | October 2010 | Phase 3 |
NCT02075528 | Taipei City Hospital|Johnson & Johnson Taiwan Ltd|Taipei Institute of Pathology | Schizophrenia|Schizoaffective Disorder | July 2009 | Phase 4 |
NCT01193166 | Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | August 2010 | Phase 4 |
NCT00396565 | Janssen Pharmaceutical K.K. | Schizophrenia | July 2006 | Phase 3 |
NCT02307396 | Technical University of Munich | Schizophrenia|Schizophrenia and Disorders With Psychotic Features|Schizoaffective Disorders | February 1, 2015 | Phase 4 |
NCT03485417 | The University of Hong Kong|Queen Mary Hospital, Hong Kong|North District Hospital | Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis)|Schizophrenia and Related Disorders|Stimulant Dependence|Stimulant Abuse|Pharmacotherapy | June 1, 2019 | Phase 2|Phase 3 |
NCT04064476 | Huazhong University of Science and Technology | Schizophrenia | August 18, 2019 | |
NCT01150448 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | September 2007 | Phase 1 |
NCT01942382 | Janssen Pharmaceutical K.K. | Schizophrenia | April 2009 | Phase 1 |
NCT01281527 | Janssen-Cilag International NV | Schizophrenia | November 2010 | Phase 3 |
NCT00791401 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Renal Impairment | April 2004 | Phase 1 |
NCT00892489 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | July 2004 | Phase 1 |
NCT00934635 | Janssen-Cilag G.m.b.H | Schizophrenia | September 2009 | Phase 4 |
NCT04940039 | Janssen-Cilag International NV | Schizophrenia | July 22, 2021 | Phase 4 |
NCT00105326 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Insomnia | February 2005 | Phase 2 |
NCT00757705 | Johnson & Johnson Taiwan Ltd | Schizophrenia | March 2008 | Phase 4 |
NCT01448720 | Janssen-Cilag Farmaceutica Ltda. | Schizophrenia | September 2011 | Phase 3 |
NCT00650793 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2004 | Phase 3 |
NCT01724359 | Janssen-Cilag, S.A. | Schizophrenia | February 2008 | Phase 4 |
NCT00892541 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | October 2004 | Phase 1 |
NCT03345979 | Alkermes, Inc. | Schizophrenia | November 15, 2017 | Phase 3 |
NCT03080194 | Maosheng Fang|Huazhong University of Science and Technology | Schizophrenia | April 2017 | Phase 4 |
NCT00309699 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder|Mood Disorders | April 2006 | Phase 3 |
NCT02462473 | Janssen Research & Development, LLC | Schizophrenia|Schizoaffective Disorder | May 2015 | Phase 2 |
NCT00330863 | Northwell Health|National Institute of Mental Health (NIMH) | Schizophrenia|Schizoaffective Disorder | May 2006 | Phase 4 |
NCT01822730 | Wei Hao|Central South University | Methamphetamine Dependence | February 2013 | Phase 4 |
NCT00210548 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | April 2005 | Phase 3 |
NCT00535132 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | October 2007 | Phase 4 |
NCT00412373 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP | Schizoaffective Disorder|Psychotic Disorder | December 2006 | Phase 3 |
NCT01451736 | University of California, Los Angeles|National Institute of Mental Health (NIMH)|Janssen Scientific Affairs, LLC | Schizophrenia (Recent-onset) | October 2011 | Phase 4 |
NCT00590577 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2007 | Phase 3 |
NCT00796835 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | July 2004 | Phase 1 |
NCT04572685 | Luye Pharma Group Ltd.|Alliance for Clinical Trials in Oncology|Evolution Research Group | Schizophrenia Patients | January 22, 2020 | Phase 1 |
NCT01009047 | Janssen Research & Development, LLC | Schizophrenia | December 2009 | Phase 3 |
NCT00334126 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP | Schizophrenia | April 2006 | Phase 3 |
NCT00397033 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP | Schizoaffective Disorder|Psychotic Disorder | November 2006 | Phase 3 |
NCT00604279 | Xian-Janssen Pharmaceutical Ltd. | Schizophrenia | January 2008 | Phase 3 |
NCT00350467 | Xian-Janssen Pharmaceutical Ltd. | Acute Schizophrenia | June 2006 | Phase 3 |
NCT00210769 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | January 2004 | Phase 3 |
NCT00937261 | University of California, Irvine|Janssen, LP | Schizophrenia | July 2009 | Phase 4 |
NCT00078039 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2004 | Phase 3 |
NCT00299715 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder|Mood Disorders | February 2006 | Phase 3 |
NCT00892320 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2004 | Phase 1 |
NCT00791167 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | June 2006 | Phase 1 |
NCT04922593 | Luye Pharma Group Ltd. | Schizophrenia|Psychotic Disorders|Mood Disorders|Schizophrenia Spectrum|Mental Disorders|Antipsychotic Agents|Tranquilizing Agents|Central Nervous System Depressants|Physiological Effects of Drugs|Psychotropic Drugs|Neurotransmitter Agents|Molecular Mechanisms of Pharmacological Action | January 13, 2021 | Phase 1 |
NCT00632229 | University of South Florida|Indiana University|Ortho-McNeil Janssen Scientific Affairs, LLC | Obsessive-Compulsive Disorder | October 2007 | Phase 2 |
NCT01795547 | H. Lundbeck A+S|Otsuka Pharmaceutical Co., Ltd. | Schizophrenia | February 2013 | Phase 3 |
NCT00796432 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2003 | Phase 1 |
NCT01670071 | Johnson & Johnson Taiwan Ltd | Schizophrenia | January 2013 | Phase 4 |
NCT00524043 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | September 2007 | Phase 4 |
NCT03809325 | Janssen-Cilag International NV | Schizophrenia | November 21, 2018 | |
NCT01399450 | Seoul National University Hospital|Johnson & Johnson | Schizophrenia | August 2011 | Phase 4 |
NCT02600741 | Janssen Scientific Affairs, LLC | Schizophrenia | July 24, 2015 | |
NCT01060228 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Epilepsy | January 2009 | Phase 1 |
NCT01742390 | Si Tianmei|Peking University | Sexual Dysfunction|Hyperprolactinemia | February 2013 | Phase 4 |
NCT01110317 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | July 2005 | Phase 1 |
NCT02146547 | UMC Utrecht | Schizophrenia | February 2015 | Phase 4 |
NCT03666715 | Janssen-Cilag Farmaceutica Ltda. | Schizophrenia | August 7, 2018 | |
NCT00488319 | Janssen Research & Development, LLC | Schizophrenia|Schizophrenic Disorders|Psychotic Disorders|Dementia Praecox | June 2007 | Phase 3 |
NCT01299389 | Janssen Pharmaceutical K.K. | Schizophrenia | October 2010 | Phase 3 |
NCT01577186 | Johnson & Johnson Taiwan Ltd | Schizophrenia | July 2008 | Phase 4 |
NCT01157585 | Chonbuk National University Hospital|Janssen Korea, Ltd., Korea | First Episode Psychosis | February 2010 | Phase 4 |
NCT00784238 | Janssen Korea, Ltd., Korea | Schizophrenia | April 2008 | Phase 4 |
NCT04754750 | Calo Psychiatric Center | Schizophrenics | January 2015 | Phase 1|Phase 2 |
NCT01860781 | Seoul National University Hospital | Schizophrenia | August 2011 | Phase 4 |
NCT00796185 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Schizoaffective Disorder | August 2003 | Phase 1 |
NCT00946985 | Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | June 2009 | Phase 4 |
NCT01662648 | Janssen Pharmaceutica | Schizophrenia | June 2007 | Phase 3 |
NCT02634463 | Janssen Research & Development, LLC | Immunoassay|Antipsychotic | November 2015 | Phase 1 |
NCT01051531 | Johnson & Johnson Pte Ltd | Schizophrenia | April 2010 | Phase 3 |
NCT03390712 | Réseau de Santé Vitalité Health Network|Janssen Inc. | Schizophrenia Spectrum and Other Psychotic Disorders | January 2, 2018 | |
NCT01825928 | Wei Hao|Central South University | Methamphetamine Dependence | February 2013 | Not Applicable |
NCT01181960 | Janssen Scientific Affairs, LLC | Schizophrenia|Bipolar Disorder | August 2010 | |
NCT00549562 | Indiana University School of Medicine|Ortho-McNeil Janssen Scientific Affairs, LLC|Indiana University | Autism | November 2007 | Phase 3 |
NCT00668837 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | February 2004 | Phase 3 |
NCT00119756 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | June 2005 | Phase 3 |
NCT03730857 | Calo Psychiatric Center | Schizophrenia | January 2008 | Phase 1 |
NCT01498770 | Organon and Co | Bipolar Disorder | April 1, 2013 | |
NCT00697658 | Janssen-Cilag B.V. | Schizophrenia | March 2008 | |
NCT01157351 | Janssen Scientific Affairs, LLC | Schizophrenia | May 2010 | Phase 4 |
NCT01685931 | Xian-Janssen Pharmaceutical Ltd. | Schizophrenia | November 2012 | Phase 4 |
NCT03557931 | Astellas Pharma Global Development, Inc.|Astellas Pharma Inc | Schizophrenia | July 13, 2018 | Phase 2 |
NCT00111189 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen-Cilag International NV | Schizophrenia | February 2005 | Phase 3 |
NCT00309686 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Affective Psychosis, Bipolar|Bipolar Disorder|Mania | April 2006 | Phase 3 |
NCT00086320 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2004 | Phase 3 |
NCT01050478 | Janssen Cilag N.V.+S.A. | Psychomotor Agitation|Acute Disease | March 2010 | Phase 4 |
NCT01561898 | Janssen Pharmaceutical K.K. | Schizophrenia | June 2006 | Phase 3 |
NCT01947803 | Xian-Janssen Pharmaceutical Ltd. | Schizophrenia | September 2013 | Phase 4 |
NCT00083668 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | April 2004 | Phase 3 |
NCT00892125 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Bipolar Disorder | September 2006 | Phase 1 |
NCT00752427 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | June 2004 | Phase 3 |
NCT01577160 | Johnson & Johnson Taiwan Ltd | Schizophrenia | May 2008 | Phase 4 |
NCT04076371 | Beijing HuiLongGuan Hospital | Schizophrenia | January 2012 | Not Applicable |
NCT00566631 | Janssen-Cilag International NV | Schizophrenia | July 2007 | Phase 3 |
NCT02431702 | Janssen Scientific Affairs, LLC | Schizophrenia|Psychotic Disorders | July 8, 2015 | Phase 3 |
NCT01541371 | Xian-Janssen Pharmaceutical Ltd. | Schizophrenia | July 2008 | Phase 3 |
NCT00796471 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | June 2003 | Phase 1 |
NCT00645099 | Janssen-Cilag International NV | Schizophrenia | October 2007 | Phase 3 |
NCT01136772 | New York State Psychiatric Institute|National Institute of Mental Health (NIMH)|Duke University|University of North Carolina, Chapel Hill | Schizophrenia|Schizoaffective Disorder | March 2011 | Phase 4 |
NCT00796640 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | September 2003 | Phase 1 |
NCT01134731 | University of Alabama at Birmingham|American Foundation for Suicide Prevention|Ortho-McNeil Janssen Scientific Affairs, LLC | Major Depressive Disorder|Suicidal Ideation | May 2010 | Phase 4 |
NCT02713282 | Janssen-Cilag Ltd. | Schizophrenia | April 28, 2016 | Phase 3 |
NCT00473434 | Janssen-Cilag Pty Ltd | Schizophrenia | April 2007 | Phase 3 |
NCT00257023 | Janssen Pharmaceutical K.K. | Schizophrenia | February 2005 | Phase 2 |
NCT01606228 | Janssen Pharmaceutica | Schizophrenia | December 2007 | Phase 3 |
NCT01584466 | University of Maryland, Baltimore | Schizophrenia | January 2014 | Not Applicable |
NCT00915512 | Janssen-Cilag Turkey | Schizophrenia | May 2009 | Phase 4 |
NCT03425552 | Pharmathen S.A. | Schizophrenia | March 11, 2018 | Phase 1|Phase 2 |
NCT01559272 | Janssen Research & Development, LLC | Schizophrenia | February 21, 2008 | Phase 1 |
NCT02433717 | National Taiwan University Hospital | Schizophrenia|Schizoaffective Disorder | April 2015 | Phase 4 |
NCT00073320 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | August 2003 | Phase 3 |
NCT00791622 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Schizoaffective Disorder | January 2006 | Phase 1 |
NCT00085748 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | August 2004 | Phase 3 |
NCT01662310 | Janssen Research & Development, LLC | Schizophrenia | June 2011 | Phase 3 |
NCT00488891 | Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia | April 2007 | |
NCT00791713 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2006 | Phase 1 |
NCT01081769 | Janssen-Cilag International NV | Schizophrenia | February 2010 | Phase 3 |
NCT00535145 | Ortho-McNeil Janssen Scientific Affairs, LLC | Schizophrenia|Schizoaffective Disorder|Psychotic Disorders | October 2007 | Phase 4 |
NCT01279213 | Universidad Nacional de Rosario | Schizophrenia|Schizophrenic Disorders|Psychotic Disorder | January 2009 | Phase 4 |
NCT00592358 | Massachusetts General Hospital | Pediatric Bipolar Disorder | November 2007 | Phase 4 |
NCT03510325 | Shanghai Mental Health Center | Schizophrenia | October 1, 2018 | Phase 4 |
NCT01362426 | Janssen-Cilag Pty Ltd | Schizophrenia | March 2011 | |
NCT00101634 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | December 2004 | Phase 3 |
NCT00077714 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | January 2004 | Phase 3 |
NCT00790777 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2007 | Phase 1 |
NCT00791349 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Schizoaffective Disorder | February 2005 | Phase 1 |
NCT00761189 | Janssen Korea, Ltd., Korea | Schizophrenia | February 2008 | Phase 4 |
NCT01527305 | Johnson & Johnson Pte Ltd | Schizophrenia | June 2012 | Phase 4 |
NCT00766064 | Yale University | Posttraumatic Stress Disorder | September 2008 | Phase 4 |
NCT00460512 | Janssen-Cilag International NV | Schizophrenia | April 25, 2007 | Phase 3 |
NCT01010776 | Janssen-Cilag Farmaceutica Ltda. | Schizophrenia | February 2008 | Phase 4 |
NCT01284959 | Chonbuk National University Hospital|AstraZeneca|Janssen Korea, Ltd., Korea|Korea Otsuka Pharmaceutical Co., Ltd.|Sanofi-Synthelabo | Schizophrenia | June 2010 | Phase 4 |
NCT01387542 | Janssen-Cilag Ltd.,Thailand | Schizophrenia | August 2009 | Phase 4 |
NCT02374567 | Hannover Medical School | Dementia|Depression|Schizophrenia|Psychosomatic Disorders|Anxiety Disorders | January 2015 | Phase 3 |
NCT00758030 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2004 | Phase 1 |
NCT02893371 | University of New Mexico|Patient-Centered Outcomes Research Institute|Montana State University|National Alliance on Mental Illness Montana|CGStat LLC|Risk Benefit Statistics LLC|National Alliance on Mental Illness New Mexico|National Alliance on Mental Illness Westside Los Angeles | Bipolar Disorder | September 2016 | |
NCT03713658 | Janssen Research & Development, LLC | Schizophrenia | October 18, 2018 | Phase 4 |
NCT00761579 | Janssen Korea, Ltd., Korea | Schizophrenia | April 2008 | Phase 4 |
NCT01211704 | University of Miami|Ortho-McNeil, Inc. | Bipolar Disorder | October 2010 | Phase 4 |
NCT01606254 | Janssen Pharmaceutical K.K. | Schizophrenia | January 2007 | Phase 2 |
NCT01193153 | Janssen Scientific Affairs, LLC | Schizoaffective Disorder | September 2010 | Phase 3 |
NCT00490971 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder | May 2006 | Phase 3 |
NCT00791284 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia|Hepatic Impairment | August 2004 | Phase 1 |
NCT01682161 | Janssen Korea, Ltd., Korea | Schizophrenia | January 2012 | Phase 4 |
NCT00827840 | Chonnam National University Hospital|Janssen Korea, Ltd., Korea|Ministry of Health, Republic of Korea | Schizophrenia | November 2008 | Phase 4 |
NCT00838669 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | August 2005 | Phase 1 |
NCT02918825 | Beijing HuiLongGuan Hospital | Schizophrenia | September 1, 2016 | Not Applicable |
NCT01362439 | Janssen-Cilag S.p.A. | Schizophrenia | January 2009 | Phase 4 |
NCT00761605 | Janssen Korea, Ltd., Korea | Schizophrenia | April 2008 | Phase 4 |
NCT00589914 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2007 | Phase 3 |
NCT01607762 | Janssen Research & Development, LLC | Healthy | February 2012 | Phase 1 |
NCT00791232 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | March 2003 | Phase 1 |